Arcus Biosciences Share Price Today
(NASDAQ: RCUS)

Name: Arcus Biosciences Share Price Today (NASDAQ: RCUS) - Arcus Biosciences Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Arcus Biosciences share price is $9.81 & ₹853.17 as on 6 Mar 2025, 2.30 'hrs' IST

$9.81

▲

0.12

(1.24%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Arcus Biosciences share price in Dollar and Rupees. Guide to invest in Arcus Biosciences stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Arcus Biosciences, along with analyst recommendations, forecasts, and comprehensive financials.

Arcus Biosciences share price movements

Today's Low: $9.42
Today's High: $9.89
$9.81
3.98%
Downside
Day's Volatility :4.75%
Upside
0.81%
52 Weeks Low: $9.64
52 Weeks High: $19.69
$9.81
1.73%
Downside
52 Weeks Volatility :51.04%
Upside
50.17%

Arcus Biosciences (RCUS) Returns

Period	Arcus Biosciences Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-43.37%	2.1%	0.0%
6 Months	-40.0%	-4.1%	0.0%
1 Year	-49.95%	2.2%	0.0%
3 Years	-70.42%	11.8%	-11.6%

Arcus Biosciences (RCUS) Key Statistics

in dollars & INR

Previous Close	$9.69
Open	$9.74
Today's High	$9.89
Today's Low	$9.42
Market Capitalization	$1.0B
Today's Volume	$418.5K
52 Week High	$19.688
52 Week Low	$9.42
Revenue TTM	$258.0M
EBITDA	$-300.0M
Earnings Per Share (EPS)	$-2.9
Profit Margin	-109.69%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-59.77%

How to invest in Arcus Biosciences Stock (RCUS) from India?

It is very easy for Indian residents to invest directly in Arcus Biosciences from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Arcus Biosciences stock in both Indian Rupees (INR) and US Dollars (USD). Search for Arcus Biosciences or RCUS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Arcus Biosciences or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Arcus Biosciences shares which would translate to 0.089 fractional shares of Arcus Biosciences as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Arcus Biosciences, in just a few clicks!

Returns in Arcus Biosciences (RCUS) for Indian investors in Rupees

The Arcus Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Arcus Biosciences investment value today

Current value as on today

₹55,634

Returns

₹44,366

(-44.37%)

Returns from Arcus Biosciences Stock

₹49,329 (-49.33%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Arcus Biosciences (RCUS)

-30%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Arcus Biosciences Stock from India on INDmoney has decreased by -30% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Arcus Biosciences

BlackRock Inc
9.16%
Vanguard Group Inc
5.09%
FMR Inc
3.83%
Woodline Partners LP
3.33%
State Street Corp
2.83%
Point72 Asset Management, L.P.
1.89%

Analyst Recommendation on Arcus Biosciences

Buy

83%Buy

16%Hold

0%Sell

Based on 18 Wall street analysts offering stock ratings for Arcus Biosciences(by analysts ranked 0 to 5 stars)

Based on 18 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Arcus Biosciences Stock (RCUS)

What analysts predicted

Upside of 222.12%

Target:

$31.60

Current:

$9.81

Insights on Arcus Biosciences Stock (Ticker Symbol: RCUS)

Price Movement
In the last 3 months, RCUS stock has moved down by -43.4%
Decreasing Revenue
Revenue is down for the last 2 quarters, 48.0M → 26.0M (in $), with an average decrease of 45.8% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -92.0M → -94.0M (in $), with an average decrease of 2.2% per quarter
RCUS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 110.7%
RCUS vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 119.1%
Price to Sales
ForRCUS every $1 of sales, investors are willing to pay $3.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

RCUS Arcus Biosciences Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$15.0M	↑ 79.58%
Net Income	$-75.9M	↑ 53.11%
Net Profit Margin	-506.21%	↑ 87.52%

	FY20	Y/Y Change
Revenue	$77.5M	↑ 416.78%
Net Income	$-116.7M	↑ 53.66%
Net Profit Margin	-150.52%	↑ 355.69%

	FY21	Y/Y Change
Revenue	$382.9M	↑ 393.93%
Net Income	$53.0M	↓ 145.42%
Net Profit Margin	13.84%	↑ 164.36%

	FY22	Y/Y Change
Revenue	$112.0M	↓ 70.75%
Net Income	$-267.0M	↓ 603.77%
Net Profit Margin	-238.39%	↓ 252.23%

	FY23	Y/Y Change
Revenue	$117.0M	↑ 4.46%
Net Income	$-307.0M	↑ 14.98%
Net Profit Margin	-262.39%	↓ 24.0%

	FY24	Y/Y Change
Revenue	$258.0M	↑ 120.51%
Net Income	$-283.0M	↓ 7.82%
Net Profit Margin	-109.69%	↑ 152.7%

	Q3 FY23	Q/Q Change
Revenue	$32.0M	↑ 10.34%
Net Income	$-71.0M	↓ 5.33%
Net Profit Margin	-221.88%	↑ 36.74%

	Q4 FY23	Q/Q Change
Revenue	$31.0M	↓ 3.12%
Net Income	$-81.0M	↑ 14.08%
Net Profit Margin	-261.29%	↓ 39.41%

	Q1 FY24	Q/Q Change
Revenue	$145.0M	↑ 367.74%
Net Income	$-4.0M	↓ 95.06%
Net Profit Margin	-2.76%	↑ 258.53%

	Q2 FY24	Q/Q Change
Revenue	$39.0M	↓ 73.1%
Net Income	$-93.0M	↑ 2225.0%
Net Profit Margin	-238.46%	↓ 235.7%

	Q3 FY24	Q/Q Change
Revenue	$48.0M	↑ 23.08%
Net Income	$-92.0M	↓ 1.08%
Net Profit Margin	-191.67%	↑ 46.79%

	Q4 FY24	Q/Q Change
Revenue	$26.0M	↓ 45.83%
Net Income	$-94.0M	↑ 2.17%
Net Profit Margin	-361.54%	↓ 169.87%

	FY19	Y/Y Change
Profit	$15.0M	↑ 79.58%

	FY20	Y/Y Change
Profit	$-81.5M	↓ 643.22%

	FY21	Y/Y Change
Profit	$375.8M	↓ 561.23%

	FY22	Y/Y Change
Profit	$98.0M	↓ 73.92%

	FY23	Y/Y Change
Profit	$-223.0M	↓ 327.55%

	FY24	Y/Y Change
Profit	$258.0M	↓ 215.7%

	Q3 FY23	Q/Q Change
Profit	$29.0M	↑ 16.0%

	Q4 FY23	Q/Q Change
Profit	$26.0M	↓ 10.34%

	Q1 FY24	Q/Q Change
Profit	$142.0M	↑ 446.15%

	Q2 FY24	Q/Q Change
Profit	$37.0M	↓ 73.94%

	Q3 FY24	Q/Q Change
Profit	$48.0M	↑ 29.73%

	Q4 FY24	Q/Q Change
Profit	$26.0M	↓ 45.83%

	FY19	Y/Y Change
Operating Cash Flow	$-73.5M	↑ 70.86%
Investing Cash Flow	$59.2M	↓ 152.2%
Financing Cash Flow	$1.1M	↓ 99.13%

	FY20	Y/Y Change
Operating Cash Flow	$111.2M	↓ 251.33%
Investing Cash Flow	$-434.4M	↓ 833.58%
Financing Cash Flow	$438.7M	↑ 38962.78%

	FY21	Y/Y Change
Operating Cash Flow	$-256.2M	↓ 330.43%
Investing Cash Flow	$-3.9M	↓ 99.11%
Financing Cash Flow	$237.3M	↓ 45.9%

	FY22	Y/Y Change
Operating Cash Flow	$438.0M	↓ 270.98%
Investing Cash Flow	$-413.0M	↑ 10577.35%
Financing Cash Flow	$33.0M	↓ 86.1%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-63.0M	↑ 10.53%
Investing Cash Flow	$11.0M	↓ 57.69%
Financing Cash Flow	$6.0M	↓ 73.91%

Arcus Biosciences Technicals Summary

Sell

Neutral

Buy

Arcus Biosciences is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Arcus Biosciences (RCUS) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Arcus Biosciences Inc	-26.59%	-40.0%	-49.95%	-70.42%	-46.17%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Arcus Biosciences Inc	14.37	NA	NA	-4.13	-0.6	-0.17	NA	5.26
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Arcus Biosciences Inc	Buy	$1.0B	-46.17%	14.37	-109.69%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Arcus Biosciences

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Organization	Arcus Biosciences
Employees	627
CEO	Dr. Terry J. Rosen Ph.D.
Industry	Health Technology

Management People of Arcus Biosciences

Name	Title
Dr. Terry J. Rosen Ph.D.	Co-Founder, Chairman & CEO
Dr. Juan Carlos Jaen Ph.D.	Co- Founder & President
Mr. Robert C. Goeltz II	Principal Financial Officer & CFO
Ms. Jennifer A. Jarrett M.B.A.	Chief Operating Officer
Dr. K. Christopher Garcia Ph.D.	Co-Founder & Member of Scientific Advisory Board
Mr. Alexander Azoy CPA	VP of Finance & Principal Accounting Officer
Dr. Jonathan Yingling Ph.D.	Chief Scientific Officer
Pia Eaves	Vice President of Investor Relations & Strategy
Ms. Carolyn C. Tang J.D.	General Counsel & Corporate Secretary
Holli Kolkey	Vice President of Corporate Communications

Important FAQs about investing in RCUS Stock from India :

What is Arcus Biosciences share price today?

Arcus Biosciences share price today stands at $9.81, Open: $9.74 ; Previous Close: $9.69 ; High: $9.89 ; Low: $9.42 ; 52 Week High: $19.69 ; 52 Week Low: $9.64.

The stock opens at $9.74, after a previous close of $9.69. The stock reached a daily high of $9.89 and a low of $9.42, with a 52-week high of $19.69 and a 52-week low of $9.64.

Can Indians buy Arcus Biosciences shares?

Yes, Indians can invest in the Arcus Biosciences (RCUS) from India.

With INDmoney, you can buy Arcus Biosciences at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Arcus Biosciences at zero transaction cost.

How can I buy Arcus Biosciences shares from India?

It is very easy to buy Arcus Biosciences from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Arcus Biosciences (RCUS) be purchased?

Yes, you can buy fractional shares of Arcus Biosciences with INDmoney app.

What are the documents required to start investing in Arcus Biosciences stocks?

To start investing in Arcus Biosciences, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.